Molecular Modeling of Human CCR2 Receptor within POPC Lipid Bilayer
- 226 Downloads
Chemokine receptor 2 (CCR2), a G-protein coupled receptor (GPCR), is a critical target for several inflammatory and autoimmune diseases. The main restriction on designing desirable antagonists against CCR2 is the lack of appropriate crystal structure for this target. In the absence of such experimental data, computational methods triggering structure prediction provide a cost-effective option. Homology modeling has been widely used to explore GPCR structure. Within the present contribution, homology modeling, molecular docking and molecular dynamics (MD) simulation were applied to construct a reliable model for CCR2. In the present contribution, we docked INCB3344, one of the most potent CCR2 inhibitors, into the active site of the CCR2 protein. Subsequently, we studied the dynamic behavior of INCB3344-CCR2 complex in the presence of lipid membrane. Moreover; a detailed molecular mechanism of INCB3344 action has been proposed. It was revealed that Tyr120, His121, Tyr259 and Glu291 formed H-bond interactions with INCB3344 while residues such as Trp98, His202, Thr203 and Thr173 participated in hydrophobic interactions. As a consequence, a reliable homology model of CCR2 could be successfully developed on the basis of CCR5 crystallographic structure. Finally it was found that binding of INCB3344 led to the structural changes in CCR2 that provided more interaction sites. Results of this study may be useful to design further CCR2 inhibiting structures with the aim of developing desirable therapeutic agents.
KeywordsHomology modeling Docking MD simulation CCR2 Inflammation INCB3344
Financial supports of this project by research council of Hamadan University of Medical Sciences are acknowledged.
- 2.Kubinyi H (2001) HTS Technologies-IBC Informa Conference. IDrugs 4(2):168–173Google Scholar
- 3.Blundell TL, Sibanda BL, Montalvão RW, Brewerton S, Chelliah V, Worth CL, Harmer NJ, Davies O, Burke D (2006) Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond Ser B Biol Sci 361(1467):413–423CrossRefGoogle Scholar
- 11.Gu L, Tseng SC, Rollins BJ (1999) Monocyte chemoattractant protein-1. Chemokines Chem Immunol Basel Karger 72:7–29Google Scholar
- 19.Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, Kaur R, Moores KE, Shillito H, Willetts J, Witherington J (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46(19):4070–4086CrossRefGoogle Scholar
- 23.Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, Kanjanapangka J, Harirchian P, Chen D, Selchau V, Ribeiro S, Schyler S, Pease JE, Horuk R, Vaidehi N (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 75(6):1325–1336CrossRefGoogle Scholar
- 47.van Gunsteren WF, Billeter S, Eising A, Hünenberger PH, Krüger P, Mark AE, Scott WRP, Tironi IG (1996) Biomolecular simulation: the GROMOS96 manual and user guide. Zurich, Switzerland: Hochschulverlag AG an der ETH Z¨urichGoogle Scholar